Tokyo Tape
Sign in
← Tohoku Chemical

Quarterly report · Q3

7446.TEDINET S100OW0Q
Period2021-10-01 → 2022-06-30
Filed2022-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥27.9bn2021-10-01 → 2022-06-30Cons.Net sales
Revenue¥36.2bn2020-10-01 → 2021-09-30Cons.Net sales (5-year summary)
Revenue¥27.2bn2020-10-01 → 2021-06-30Cons.Net sales
Operating income¥763m2021-10-01 → 2022-06-30Cons.Operating income
Operating income¥572m2020-10-01 → 2021-06-30Cons.Operating income
Ordinary income¥814m2021-10-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥759m2020-10-01 → 2021-09-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥608m2020-10-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥786m2021-10-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥612m2020-10-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥539m2021-10-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥517m2020-10-01 → 2021-09-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥428m2020-10-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥559m2021-10-01 → 2022-06-30Cons.Profit loss
Net income¥446m2020-10-01 → 2021-06-30Cons.Profit loss
Total assets¥15.0bnat 2022-06-30Cons.Assets
Total assets¥16.1bnat 2021-09-30Cons.Assets
Total assets¥16.2bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥8.5bnat 2022-06-30Cons.Liabilities
Total liabilities¥9.8bnat 2021-09-30Cons.Liabilities
Net assets / equity¥6.6bnat 2022-06-30Cons.Net assets
Net assets / equity¥6.3bnat 2021-09-30Cons.Net assets
Net assets / equity¥6.1bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥1.3bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥799mat 2021-09-30Cons.Cash and deposits
EPS (basic)¥596.992021-10-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥185.032022-04-01 → 2022-06-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥564.912020-10-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥467.382020-10-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥114.172021-04-01 → 2021-06-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio43.2%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio38.6%at 2021-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio37.3%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Otherother segmentsrevenue2021-10-01 → 2022-06-30¥318m
Otherother segmentsrevenue external2021-10-01 → 2022-06-30¥318m
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue2021-10-01 → 2022-06-30¥2.4bn
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue external2021-10-01 → 2022-06-30¥2.4bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue2021-10-01 → 2022-06-30¥13.8bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue external2021-10-01 → 2022-06-30¥13.8bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue2021-10-01 → 2022-06-30¥11.4bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue external2021-10-01 → 2022-06-30¥11.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-10-01 → 2022-06-30¥27.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-10-01 → 2022-06-30¥27.9bn
Otherother segmentsrevenue2020-10-01 → 2021-06-30¥331m
Otherother segmentsrevenue external2020-10-01 → 2021-06-30¥331m
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue2020-10-01 → 2021-06-30¥2.5bn
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue external2020-10-01 → 2021-06-30¥2.5bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue2020-10-01 → 2021-06-30¥13.4bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue external2020-10-01 → 2021-06-30¥13.4bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue2020-10-01 → 2021-06-30¥10.9bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue external2020-10-01 → 2021-06-30¥10.9bn
Total Of Reportable Segments And Otherssegment totalrevenue2020-10-01 → 2021-06-30¥27.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2020-10-01 → 2021-06-30¥27.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 381
ItemContextValueUnit
Noncurrent assetsPrior1YearInstant5127446000JPY
Noncurrent assetsCurrentQuarterInstant4653653000JPY
AssetsPrior1YearInstant16128570000JPY
AssetsCurrentQuarterInstant15032596000JPY
Notes and accounts payable tradePrior1YearInstant7811196000JPY
Notes and accounts payable tradeCurrentQuarterInstant6698876000JPY
Electronically recorded obligations operating clPrior1YearInstant285833000JPY
Electronically recorded obligations operating clCurrentQuarterInstant358315000JPY
Short term loans payablePrior1YearInstant156200000JPY
Short term loans payableCurrentQuarterInstant97400000JPY
Current portion of long term loans payablePrior1YearInstant14280000JPY
Current portion of long term loans payableCurrentQuarterInstant14280000JPY
Lease obligations clPrior1YearInstant179529000JPY
Lease obligations clCurrentQuarterInstant159274000JPY
Income taxes payablePrior1YearInstant137276000JPY
Income taxes payableCurrentQuarterInstant112150000JPY
Provision for bonusesPrior1YearInstant57450000JPY
Provision for bonusesCurrentQuarterInstant12300000JPY
Other clPrior1YearInstant256280000JPY
Other clCurrentQuarterInstant240903000JPY
Current liabilitiesPrior1YearInstant8898046000JPY
Current liabilitiesCurrentQuarterInstant7693500000JPY
Long term loans payablePrior1YearInstant55970000JPY
Long term loans payableCurrentQuarterInstant45260000JPY
Lease obligations nclPrior1YearInstant308671000JPY
Lease obligations nclCurrentQuarterInstant219556000JPY
Deferred tax liabilitiesPrior1YearInstant310294000JPY
Deferred tax liabilitiesCurrentQuarterInstant244552000JPY
Net defined benefit liabilityPrior1YearInstant99801000JPY
Net defined benefit liabilityCurrentQuarterInstant94389000JPY
Provision for directors retirement benefitsPrior1YearInstant123541000JPY
Provision for directors retirement benefitsCurrentQuarterInstant128760000JPY
Other nclPrior1YearInstant50532000JPY
Other nclCurrentQuarterInstant44891000JPY
Noncurrent liabilitiesPrior1YearInstant948811000JPY
Noncurrent liabilitiesCurrentQuarterInstant777411000JPY
LiabilitiesPrior1YearInstant9846857000JPY
LiabilitiesCurrentQuarterInstant8470912000JPY
Capital stockPrior1YearInstant820400000JPY
Capital stockCurrentQuarterInstant820400000JPY
Capital surplusPrior1YearInstant881100000JPY
Capital surplusCurrentQuarterInstant881100000JPY
Retained earningsPrior1YearInstant3894043000JPY
Retained earningsCurrentQuarterInstant4375582000JPY
Treasury stockPrior1YearInstant-133566000JPY
Treasury stockCurrentQuarterInstant-168907000JPY
Shareholders equityPrior1YearInstant5461977000JPY
Shareholders equityCurrentQuarterInstant5908175000JPY
Valuation difference on available for sale securitiesPrior1YearInstant771562000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant584848000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2021-09-30pass rounding
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2021-09-30pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2020-10-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2022-06-30pass
statement vs summary · revenueconsolidated 2020-10-01/2021-06-30pass
statement vs summary · revenueconsolidated 2021-10-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2021-09-30pass
statement vs summary · total assetsconsolidated 2022-06-30pass